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ABSTRACT: CDK9 is the kinase of positive transcription elongation factor b and facilitates the
transition of paused RNA polymerase II to processive transcription elongation. CDK9 is a validated
target for the treatment of cancer, cardiac hypertrophy, and human immunodeficiency virus. Here we
analyze different CDK9/cyclin T variants to identify a form of the complex amenable to use in
inhibitor design. To demonstrate the utility of this system, we have determined the crystal structures
of CDK9/cyclin T and CDK2/cyclin A bound to the CDK9-specific inhibitor CAN508. Comparison
of the structures reveals CDK9-specific conformational changes and identifies a CDK9-specific
hydrophobic pocket, adjacent to the αC-helix. By comparison with a previously published structure
of CDK9/cyclin T/human immunodeficiency virus TAT we find that the CDK9 αC-helix has a
degree of conformational variability that has the potential to be exploited for inhibitor design.
M
any cancer cells rely on the production of anti-apoptotic
factors for their survival. Inhibition of mRNA synthesis
and the consequent down regulation of anti-apoptotic factors is
therefore an attractive strategy for cancer treatment. mRNA
synthesis by RNA polymerase II (pol II) is regulated by the
phosphorylation of its C-terminal domain (CTD) by a range of
cyclin-dependent kinases (CDKs) CDK7−CDK9, CDK12, and
CDK13. Since the discovery that the CDK inhibitor flavopiridol
induces apoptosis by inhibiting CDK9,
1 the enzyme has been a
target for anticancer drug design. Subsequent studies
established that other CDK inhibitors exploit the same
mechanism.
2−8 In addition to oncology, CDK9 has also been
validated as a drug target in virology and cardiology.
9,10 While
there are several promising compounds with high affinity for
CDK9, their selectivity toward this CDK family member is
limited. To exploit CDK9 inhibition for the treatment of these
diseases, it is crucial to obtain CDK inhibitors with a high
degree of selectivity and potency for CDK9.
CAN508 is an arylazopyrazole compound that inhibits
CDK9 with an IC50 of 0.35 μM and exhibits a 38-fold
selectivity for CDK9/cyclin T over other CDK/cyclin
complexes.
3 As is consistent with these properties, CAN508
treatment inhibits the growth of various cancer cell lines and
induces apoptosis through mechanisms that include inhibition
of pol II CTD phosphorylation and mRNA synthesis, and
induction of the tumor suppressor protein p53.
3,11 More
recently, CAN508 has also been shown to inhibit angiogenesis
through a CDK9-dependent mechanism.
11
Structure-aided drug design requires readily crystallizable
protein that can routinely generate inhibitor co-crystals
diffracting to sufficient resolution. To date, structures of the
apo form of CDK9/cyclin T as well as complexes bound to
ATP and CDK9-selective inhibitors have been determined.
12,13
In addition the structure of a CDK9/cyclin T/HIV TAT
complex has been reported.
14
Here we evaluate the usefulness of the existing CDK9/
cyclinT crystal systems for inhibitor design studies. A
comparison of the different crystal forms reveals that CDK9/
cyclin T has a degree of conformational flexibility that can be
exploited for inhibitor design. Serendipitous mutations in
CDK9/cyclin T resulted in a form of the complex that has
produced crystals that diffract up to 2.5 Å resolution.
12 We
show that this mutated form has largely unaltered kinetic,
structural, and inhibitor binding properties but offers a number
of advantages over the wild-type protein for inhibitor design
studies. To demonstrate the advantages of comparative CDK
structural studies for the design of selective CDK9 inhibitors,
we have solved the crystal structures of active CDK9/cyclin T
and CDK2/cyclin A bound to the inhibitor CAN508.
Comparison of the CDK9/cyclin T- and CDK2/cyclin A-
CAN508 co-crystal structures reveals that the inhibitor adopts
slightly different orientations within the ATP binding sites of
the two kinases. Our results identify a CDK9-specific
hydrophobic pocket that may be exploited to design inhibitors
with increased selectivity toward CDK9.
The CDK9/cyclin T crystal form used for inhibitor binding
studies to date was first reported by Baumli and colleagues.
12
This crystal form offers a number of advantages for inhibitor
studies, namely: (i) reproducible crystallization conditions that
generate crystals that diffract to 2.5−3.0 Å resolution, (ii) a
CDK9 ATP binding site that is freely accessible for inhibitor
soaking experiments, and (iii) a lack of crystal contacts at the
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conformational changes. These crystals result from a CDK9/
cyclin T complex that contains three point mutations in the
cyclin T sequence at residues Q77R, E96G, and F241L,
12 and
we therefore designate the triple mutant CDK9/
cyclin TQ77R/E96G/F241L.
While CDK9/cyclin TQ77R/E96G/F241L crystallizes reliably,
attempts to crystallize wild-type cyclin T in complex with
CDK9 resulted in very small crystals that proved unsuitable for
structural analysis. We therefore investigated the locations of
the three mutations in the crystal structure. F241L is located in
the C-terminal cyclin helix that is involved in crystal contacts.
The mutation might contribute to the improved crystallization
properties of CDK9/cyclin TQ77R/E96G/F241L. Q77R lies on a
surface loop on cyclin T and is a natural variant of the cyclin
sequence (UniProt entry: O60563). E96G is located at the
CDK/cyclin interface, and mutation to a glycine residue might
influence the interaction of cyclin T with CDK9.
To dissect the contributions that each mutation makes to the
structure of CDK9/cyclin TQ77R/E96G/F241L, we crystallized a
complex that is wild-type at cyclin T positions Gln77 and
Glu96 but retains the F241L mutation to aid crystallization. We
solved the structure of this complex at 3.2 Å resolution
(Table 1). In CDK9/cyclin TF241L Glu96 of cyclin T hydrogen
bonds to and reorients the side chain of CDK9 Arg65. Both
cyclin T Glu96 and CDK9 Arg65 participate in the same
hydrogen bonding network that is observed in the CDK9/
cyclin T/TAT structure (PDB id: 3MI9).
14 Despite the
additional contact between the CDK and cyclin subunits the
structure is very similar to that of CDK9/cyclin TQ77R/E96G/F241L
(rmsd 0.93 Å over all CDK9 atoms compared to 3BLH and
rmsd 1.3 Å compared to 3MI9; Supplementary Figure S1,
Supplementary Table 1). The side chain of Gln77, like Arg77 in
the CDK9/cyclin TQ77R/E96G/F241L structure, points out into
solvent and makes no intra- or intermolecular contacts. Taken
together these results indicate that the mutations present in
CDK9/cyclin TQ77R/E96G/F241L do not influence the overall
conformations of CDK9, cyclin T, or the CDK9/cyclin T
complex. In particular we can exclude the possibility that
conformational differences between PDB id's 3MI9 and 3BLH
result from the E96G mutation in cyclin T present in PDB id
3BLH.
Although they do not introduce a significant structural
perturbation, the mutations present in CDK9/
cyclin TQ77R/E96G/F241L might affect CDK9/cyclin T stability
and kinetic parameters. To test this hypothesis, we first
analyzed the thermal stability of the CDK9/cyclin T variants.
While CDK/cyclin complexes composed of either the wild-type
proteins or cyclin TF241L have very similar melting temperatures
(Tm) of 52.6 ± 0.16 and 51.8 ± 1.1 °C, respectively, the triple
mutant complex, CDK9/cyclin TQ77R/E96G/F241L denatures at a
lower temperature of 48.25 ± 0.58 °C (Supplementary Figure
S2a). The lower Tm of this complex most likely results, at least
in part, from the loss of the hydrogen bonding network in
which Glu96 participates.
To determine whether this lowered Tm has an impact on
inhibitor binding to the mutant CDK9/cyclin T, we employed
differential scanning fluorimetry (DSF), a technique that
exploits the fact that ligand binding to a protein increases its
thermal stability and hence its apparent melting temperature
(ΔTm). The ΔTm measured is related to the binding affinity of
the ligand for the protein and is dependent upon the ligand
concentration. It also reflects the constituent thermodynamic
properties of the ligand binding event that includes ΔS and
ΔCp.
15 A set of ΔTm values measured for a given enzyme
bound to a diverse panel of ligands can, therefore, provide a
fingerprint that is characteristic of the ligand binding properties
of that enzyme. The fingerprints of two different enzymes can
be quantitatively compared by evaluating the R2 linear
correlation coefficient between sets of inhibitor-induced ΔTm
values measured for those enzymes.
Table 1. Crystallographic Parameters
CDK9/cyclin TQ77R/E96G/F241L
/CAN508
CDK9/cyclin TF241L
/CAN508 CDK9/cyclin TF241L CDK2/cyclin A/CAN508
Data Collection
beamline ESRF ID29 DLS I24 DLS I24 DLS I02
space group H3 H3 H3 P212121
unit cell (Å) a = b = 173.42; c = 97.9 a = b = 173.30; c = 97.22 a = b = 173.6; c = 97.47 a = 74.05; b = 134.57; c =
148.28
α = β =9 0 °; γ = 120° α = β =9 0 °; γ = 120° α = β =9 0 °; γ = 120° α = β = γ =9 0 °
resolution (highest resolution
shell) (Å)
43.36−2.95 (3.11−2.95) 49.00−3.20 (3.29−3.20) 59.52−3.23 (3.41−3.23) 44.86−2.00 (2.11−2.00)
total observations 84542 (12557) 61839 (4669) 58769 (8830) 397326 (56907)
unique 23081 (3394) 17892 (1327) 17300 (2557) 100421 (14505)
Rmerge 0.072 (0.59) 0.051 (0.54) 0.070 (0.49) 10.3 (0.57)
multiplicity 3.7 (3.7) 3.5 (3.5) 3.4 (3.5) 4.0 (3.9)
mean I/σI 13.3 (1.9) 15.1 (2.0) 9.9 (2.4) 8.8 (2.2)
completeness 99.8% (100%) 99.8% (99.9%) 98.8% (99.7%) 99.8% (97.0%)
Refinement Statistics
highest resolution shell (Å) 3.08−2.95 3.40−3.20 3.44−3.23 2.02−2.00
total no. of atoms 4587 4358 4489 18970
no. of waters 8 NA NA 913
R 0.176 (0.314) 0.177 (0.259) 0.163 (0.242) 0.1877 (0.269)
Rfree (highest resolution shell) 0.221 (0.358) 0.226 (0.318) 0.210 (0.310) 0.2266 (0.301)
rms bonds 0.005 0.013 0.009 0.007
rms angles 0.842 1.526 1.344 1.038
ACS Chemical Biology Letters
dx.doi.org/10.1021/cb2004516 | ACS Chem. Biol. 2012, 7, 811−816 812To analyze the effect of the cyclin T mutations on the
interactions between CDK9 and ATP-competitive inhibitors,
we tested the ability of known CDK9 inhibitors (DRB,
CAN508, (S)-CR8, Roscovitine, Staurosporine, AMPPNP,
and Wang compound 8
2) to stabilize the different CDK9/
cyclin T complexes. The profiles of inhibitor-induced Tm shifts
for wild-type CDK9/cyclin T and the mutant complexes are
very similar (R2 > 0.93 for all combinations of CDK9/cyclin T
variants tested (Figure 1a)). For comparison, the R2 value
obtained when comparing the ΔTm values measured for
CDK2/cyclin A with those obtained for wild-type CDK9/
cyclin T is significantly lower (R2 = 0.33), as expected (Figure
1a). These results indicate that, despite slightly lowering the
enzyme's inherent Tm, the three mutations within CDK9/cyclin
TQ77R/E96G/F241L do not result in detectable changes to the
inhibitor binding properties of the CDK9 ATP-binding site.
Finally we analyzed whether the three cyclin T mutations
together affect the catalytic activity of the CDK9/
cyclin TQ77R/E96G/F241L complex. To this end we determined
the kinetic properties of both the wild-type and triple mutant
complexes with respect to the ATP substrate and the inhibitor
CAN508. Both complexes have a KMapp, ATP of 95 μM (Figure
1b), indicating that ATP binding is not affected by the presence
of the mutations. This result is in agreement with the results of
the DSF experiments. However, we did observe a decrease in
the Vmax for the CDK9/cyclin TQ77R/E96G/F241L complex (Figure
1b). CAN508 inhibits both kinase complexes with an IC50 of
0.75 μM (Supplementary Figure S2b), in good agreement with
previously published results.
3
The close agreement between the ΔTm, KMapp, ATP, and
CAN508 IC50 values for the wild-type and mutant complexes
indicates that the mutations do not affect ATP or inhibitor
binding to CDK9 or the complex’s catalytic activity. Taken
t o g e t h e r ,o u rs t r u c t u r a l ,t h e r m o d y n a m i c ,a n de n z y m a t i c
experiments validate the use of CDK9/cyclin TQ77R/E96G/F241L
for structural analysis.
To rationalize the observed selectivity of CAN508 toward
CDK9 over other CDKs, we determined structures of CAN508
bound to CDK9/cyclin T and to CDK2/cyclin A (Figure 2).
W eu s e db o t hC D K 9 / c y c l i nT F241L and CDK9/
cyclin TQ77R/E96G/F241L variants for our crystallographic studies.
In agreement with our observations described above, both
structures are highly similar, and the inhibitor electron density
within both CDK9 active sites supports a shared binding mode
(Supplementary Figure S3).
CAN508 binds to the ATP binding site located between the
N- and C-terminal lobes of the CDK9 fold and is sandwiched
between Ala46 in the N-terminal and Leu156 in the C-terminal
lobe. As is observed for most ATP-competitive inhibitors,
CAN508 makes hydrogen bonds to the CDK9 backbone in the
hinge region.
16 N16 and N14 of the diaminopyrazole ring are a
hydrogen bond donor and acceptor, respectively, to the main
Figure 1. Comparison of different CDK9/cyclin T variants. (a) Correlation between inhibition profiles of CDK9/cyclin T variants and CDK2/
cyclin A. Each data point represents the average ΔTm of three curves. The internal correlation within a data set is R2 > 0.9. Individual denaturation
profiles can be found in Supplementary Figure S2a. (b) Activity of CDK9/cyclin T and CDK9/cyclin TQ77R/E96G/F241L in the presence of increasing
amounts of ATP. Measurements were done in triplicates and confirmed in independent experiments. Error bars indicate standard errors.
ACS Chemical Biology Letters
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Cys106, mimicking the interactions made by N6 and N1 of the
purine ring of ATP (Figure 2b).
12 In addition N13 contacts the
main chain oxygen of Cys106. All of these inhibitor−CDK
interactions are conserved in the CDK2-bound structure.
In a previously determined structure of CAN508 bound to
monomeric CDK2, the inhibitor has been described as
adopting a different and markedly strained conformation.
3
Our structure of CAN508 bound to active CDK2/cyclin A is
likely to provide a more useful model by which to understand
the selectivity displayed by the inhibitor.
Although CAN508 forms similar interactions when bound to
CDK9/cyclin T and CDK2/cyclin A, there is an additional
interaction between CAN508 N12 and the carbonyl group of
Ile25 of CDK9, made possible by a movement of the glycine-
rich loop toward the ATP binding pocket (Figure 2a, c). This
rearrangement of the active site does not occur in CDK2 upon
CAN508 binding but has been observed to accompany the
binding to CDK9 of a number of ATP-competitive inhibitors
with very different chemical scaffolds.
12,13 In all these structures
the glycine-rich loop is restrained in its downward position by a
concomitant downward movement of the β3-αC loop. These
movements cause the CDK9 glycine-rich loop residues to
contribute to the formation of a solvent-excluded channel into
which inhibitors are sequestered and are qualitatively different
to inhibitor-induced changes in CDK2. We note, however, that
the glycine-rich loop is relatively flexible in both apo and
inhibitor bound conformations, as judged from high temper-
ature factors.
The higher conformational variability of CDK9 as compared
to other CDK/cyclin complexes may offer an opportunity to
enhance inhibitor potency and selectivity. In both CDK9/cyclin
T/CAN508 structures, conformational changes result in
optimal accommodation of the inhibitor in the ATP binding
site. The ability to induce these CDK9-specific conformational
changes may be a general characteristic of inhibitors that show
good selectivity toward CDK9.
The binding mode of CAN508 to CDK2/cyclin A and to
CDK9/cyclin T is very similar, but the inhibitor does adopt
somewhat different orientations within the two ATP binding
sites. The inhibitor phenolic moiety forms an aromatic contact
with the CDK9 gate-keeper residue Phe103 (CDK2 Phe80) (d
= 3.1 Å, interplanar angle = 120°) and exploits the hydrophobic
pocket lined by Phe168 at the back of the ATP binding site.
Within the CDK9-bound structure, the OH-group of the
CAN508 phenolic moiety engages in a network of hydrogen
bonds with residues Glu66, Lys48, and the backbone nitrogen
of Phe168 (Figure 2c). In CDK2 this network only extends to
include Glu51 and Lys33 (Figure 2d). This difference results
from the displacement of CDK9 Glu66 by approximately 1 Å
with respect to the CDK2 structure to generate a larger binding
pocket close to Phe168 that can better accommodate the
Figure 2. Structures of CDK2/cyclin A/CAN508 and CDK9/cyclin T/CAN508. (a) CDK2 (orange) and CDK9 (green) are shown as ribbon
representations, with CAN508 molecules as stick models. The glycine-rich loop is indicated. (b) Chemical structure of CAN508. (c, d) The CDK9/
cyclin T (c) and CDK2/cyclin A (d) ATP binding sites complexed with CAN508. Contacting residues within 3.5 Å are drawn as stick models, and
hydrogen bonds are indicated by dotted lines. (e) Superposition of selected ATP binding site residues in active CDK2 (orange) and CDK9 (green).
CDK9 residues are labeled. Figures were prepared using PyMOL.
ACS Chemical Biology Letters
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S3d). Interestingly, a CAN508 derivative lacking the OH group
on its phenyl moiety still inhibits CDK9 but not the other
CDKs tested.
3 While all phenyl derivatives tested showed
activity toward CDK9, substitution on the phenyl ring with an
o-NO2 or m-OH moiety recovered some activity toward the
other CDKs possibly by forming equivalent hydrogen bonds to
those made by the phenolic OH of CAN508.
The hydrophobic pocket in CDK9 exploited by CAN508
results from a displaced αC-helix. αC is the only helix in the N-
terminal lobe of a canonical eukaryotic kinase fold and has been
shown to adopt different conformations dependent on the
enzyme’s activation state.
17 To determine whether αC-helix
displacement is apparent in other CDK9 structures, we
compared the structures of CDK9/cyclin T (PDB id:
3BLQ
12) and CDK9/cyclin T/TAT (PDB id: 3MIA
14). To
analyze potential differences in the position of the αC-helix we
superimposed the two complexes on their C-terminal kinase
domains. As expected, we observed very little difference in the
conformations of the kinase C-terminal lobes including the
activation segment (rmsd 1.25 Å over all atoms (Figure 3)).
While the relative orientations of the N- and C-terminal kinase
lobes vary slightly between the two structures, all catalytically
important residues superpose well and adopt the functionally
relevant conformations as seen for other kinases,
18,19 indicating
that both crystal structures represent active kinase conforma-
tions. The N-terminal kinase lobes vary in the conformations of
the flexible regions (i.e., the glycine-rich loop and the β3-αC
loop) as well as in the position of the αC-helix (Figure 3). As
cyclin T associates with CDK9 through the N-terminal kinase
lobe and the αC-helix, the repositioning of the αC-helix leads
to a shift in the position of the cyclin as described.
14 Taken
together, these observations suggest that the different
conformations observed for the αC-helix likely reflect the
inherent flexibility of this region of the protein.
Our studies validate the use of CDK9/cyclin TQ77R/E96G/F241L
for the determination of inhibitor co-crystal structures. Our
data suggest that the increased overall flexibility of CDK9,
particularly in respect to the glycine-rich loop and the αC-helix
conformations, together with its more extended ATP binding
pocket, offer an opportunity to develop CDK9-specific
inhibitors. Repositioning of the αC-helix is a widely exploited
mechanism by which the activities of protein kinases are
modulated.
18 However, it appears that the particular flexibility
apparent in CDK9 allows it to adopt a conformation that
optimizes the interactions that can be made by CAN508. It will
be important to determine if this mechanism for specificity also
discriminates between CDK9 and functionally related kinases
such as CDK12 and CDK13. Such discrimination would allow
studies to dissect the individual contributions of these CDKs in
regulating transcription and further the design of specific
inhibitors to modulate the cellular levels of anti-apoptotic
factors.
■ METHODS
Protein Purification, Crystallization, and Structure Determi-
nation. CDK9 (residues 1−330)/cyclin T (residues 1−259) and
CDK2/cyclin A complexes were prepared and crystallized as
previously described.
12,19 For structure determination of CDK9/
cyclin T/CAN508 complexes, crystals were soaked for 1 h to overnight
in the crystallization condition saturated with CAN508 containing 18%
glycerol and then cryo-cooled in liquid nitrogen. Purified CDK2/
cyclin A was incubated with 7.5 mM CAN508 for 30 min on ice, and
the inhibitor complex was co-crystallized. All structures were solved as
described previously.
13
Kinetic Analysis. To determine the IC50 values toward CAN508,
10 ng of CDK9/cyclin T or CDK9/cyclin TF241L complex were
incubated with 24 μg of GST-CTD in 10 μL reactions containing 10
mM MgCl2, 50 mM HEPES pH 7.5, 100 μM ATP, 5 mM DTT, 0.2
μCi γ-32P-labeled ATP, and increasing amounts of CAN508. Reactions
were incubated for 5 min at 30 °C and terminated by the addition of
Figure 3. Superposition of CDK9/cyclin TQ77R/E96G/F241L (PDB id: 3BLQ, green and brown) and CDK9/cyclin T/TAT (PDB id: 3MIA, lilac and
rose). Structures are represented as cartoon models, with catalytically important residues as stick models. The kinase subunits were superposed on
their C-terminal kinase domains (residues 111−315). TAT is omitted for clarity.
ACS Chemical Biology Letters
dx.doi.org/10.1021/cb2004516 | ACS Chem. Biol. 2012, 7, 811−816 815SDS sample buffer. KMapp toward the ATP substrate were determined
under the same reaction conditions using 26 μg/mL GST-CTD.
Samples were analyzed by SDS-PAGE and autoradiography. Data were
fitted with GraphPad Prism version 5.02 (www.graphpad.com).
Differential scanning fluorimetry experiments were done as described
previously.
13
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